10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
US biotech firm Celgene, now a subsidiary of Bristol-Myers Squibb, plans to pursue a New Drug Application (NDA) in first-quarter 2020 for its formulation of oral azacitidine (CC-486) after data from the Phase III QUAZAR AML-001 trial showed that maintenance therapy can prolong the overall survival (OS) of acute myeloid leukemia (AML) patients compared with placebo 15 January 2020
An Expert View column on the need for bosses in the life sciences to understand financing trends from David Diamond, managing director of CBIZ MHM, an accounting and
professional services provider, 14 January 2020
French oncology-focussed Innate Pharma late yesterday announced that the French National Agency for Medicines and Health Product Safety (ANSM) has agreed that the lacutamab (IPH4102) TELLOMAK Phase II trial can resume recruitment of new patients with relapsed/refractory Sézary syndrome and mycosis fungoides (MF) who have received at least two lines of prior systemic therapy. 14 January 2020
T-cell therapy company Adaptimmune Therapeutics saw its shares close up 200% at $3.99 on Monday, having rocketed nearly 300%, on encouraging research results and the news that it has entered into a co-development and co-commercialization agreement with Japanese pharma major Astellas Pharma to bring new stem-cell derived allogeneic T-cell therapies to people with cancer that could be worth nearly $900 million. 14 January 2020
Swiss pharma giant Novartis has announced a deal with the National Health Service (NHS) that will bring English patients with atherosclerotic cardiovascular disease (ASCVD) access to inclisiran. 14 January 2020
UK-based drugmaker EUSA Pharma and China’s BeiGene have entered into an exclusive development and commercialization agreement for the orphan biologic products Sylvant (siltuximab) and Qarziba (dinutuximab beta). 13 January 2020
The impact of durable and potentially curative cell and gene therapies on health system costs has been assessed in a report published by the Alliance for Regenerative Medicine (ARM). 13 January 2020
After US biotech major Biogen scrapped development of its experimental Alzheimer’s drug aducanumab in March last year, but resuming development in October, the company has now announced an agreement to acquire an early-stage central nervous system (CNS) candidate from Pfizer. 13 January 2020
US gene therapy company bluebird bio has announced the first launch anywhere of Zynteglo (autologous CD34+ cells encoding βA-T87Q-globin gene). 13 January 2020
German drugmaker MorphoSys and Incyte have entered into a collaboration and license agreement to further develop and commercialize the anti-CD19 antibody tafasitamab (MOR208) globally. 13 January 2020
A group of three new treatments for acute migraine have been assessed by the Institute for Clinical and Economic Review (ICER) to deem what a fair US price for these yet-to-be-launched medicines might look like. 13 January 2020
AstraZeneca and partner Merck & Co today announced that a supplemental New Drug Application for Lynparza (olaparib) in combination with bevacizumab has been accepted and granted Priority Review in the USA for the maintenance treatment of patients with advanced ovarian cancer who are in complete or partial response to first-line platinum-based chemotherapy with bevacizumab. 13 January 2020
Clinical-stage USA-based biotech Aruvant Sciences says that the US Food and Drug Administration has granted Rare Pediatric Disease designation to ARU-1801, Aruvant’s investigational therapy for the treatment of sickle cell disease, an inherited blood disorder. 13 January 2020
Danish allergy immunotherapy specialists ALK-Abelló has initiated a new Phase III trial in China for its house dust mite (HDM) allergy program. 13 January 2020
Venture capital-backed Canadian biotech firm Chinook Therapeutics has entered into a license agreement with US major AbbVie for worldwide, exclusive rights to atrasentan, an endothelin receptor antagonist. 13 January 2020
New York-listed biopharma company Akari Therapeutics today announced positive interim data from its Phase III PNH CAPSTONE study in complement inhibitor naïve, transfusion-dependent paroxysmal nocturnal hemoglobinuria (PNH) patients. 10 January 2020
Swiss biotech NBE-Therapeutics has closed a $22 million Series C financing round, led by its existing shareholders Boehringer Ingelheim Venture Fund and the PPF Group, along with participation from all private shareholders. 10 January 2020
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024